CVX heads into its Q1 2026 results on May 1 with a telling divergence: the Street has been lifting targets through a month that knocked the stock down more than 10%.
The analyst move has been notably one-directional. Across the past six weeks, targets have risen at Citi (to $235), Wells Fargo (to $222), Piper Sandler (to $242), RBC Capital (to $220), and Morgan Stanley (to $212) — all maintaining bullish ratings. The most recent action, from BNP Paribas on April 17, was an outright upgrade to Outperform at a $174 target, suggesting even more cautious voices are warming to the name. Scotiabank kept a Sector Perform rating but raised its target to $187 earlier this week. The consensus mean target of $211 implies roughly 12% upside from the current $188.36, and the analyst recommendation differential ranks in the 88th percentile across the universe. The bull case centres on accelerating free cash flow, $3–4 billion in targeted cost reductions by end-2026, and AI-driven tools improving shale productivity. Bears flag limited project visibility outside Guyana and the Eastern Mediterranean and point to capital expenditure guidance cuts as a sign of caution about longer-horizon growth.
The borrow market is almost entirely relaxed about Chevron. Short interest has dropped sharply — off roughly 19% over the past month — to just under 1% of the free float, one of the lowest readings in the dataset. Cost to borrow has more than halved since late March, ending the week near 0.20% annualised. Availability in the lending pool is abundant: far more shares are available to borrow than are currently shorted, leaving no meaningful friction for anyone wanting to put on or cover a short. The ORTEX short score of 28.4 places CVX well into the lower end of the range, consistent with a stock where bearish conviction is fading rather than building.
Options positioning is slightly more cautious than usual without being alarming. The put/call ratio ended the week at 0.79, a touch above its 20-day average of 0.78 — a z-score of just 0.48, well within normal bounds. The PCR 52-week range runs from 0.60 to 0.93, so the current level is neither elevated nor depressed. It reads as balanced hedging rather than a directional bet ahead of the print.
Insider activity through March is worth noting. CEO Mike Wirth sold roughly $23 million in shares on March 2, with the Executive Vice Chairman and Chief Legal Officer also selling on the same day. A further CLO sale of $8.6 million was recorded on March 30. All trades carry a low significance score, and the dates suggest scheduled or plan-driven disposals rather than conviction selling. Still, net insider activity over the past 90 days was a net sell of around $128 million in value — a figure that reads more as routine monetisation at elevated prices than a bearish signal, given the stock was trading above $190 at the time of the largest tranches.
Institutional ownership reflects CVX's mega-cap defensive status. Vanguard, State Street, and BlackRock together hold close to 24% of shares. State Street added over 6 million shares in Q1, the largest new build among the top holders. Berkshire Hathaway remains the fourth-largest holder at 6.5% of shares, though its last reported date is December 2025 — its next 13F will be the one to watch for any Buffett-driven signal.
The earnings history is thin but directionally positive. The last quarterly release, on January 30, delivered a 1.7% gain the next day and a 5.6% move over the five sessions that followed. With EPS momentum ranking in the 88th percentile over 30 and 90 days, and an EV/EBITDA multiple of roughly 7x, the setup heading into May 1 is of a stock that has cheapened meaningfully on a softer crude backdrop — and where the question is whether Q1 volumes and free cash flow can validate the upward revisions the Street has been making all month. Peer names XOM and COP both gained on the week, with COP up 3.4% and OXY outpacing the group at 4%, making CVX's more modest 1.3% weekly gain worth monitoring as a relative-performance tell after the results land.
See the live data behind this article on ORTEX.
Open CVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
